SignificanceAkin to other physiological responses, immune functions can be modified in humans through associative conditioning procedures as part of a learned placebo response. However, it is unclear whether learned immune responses can be produced in patient populations already receiving an immunosuppressive regimen. In the present study, we demonstrate in renal transplant patients who were already receiving immunosuppressive treatment that learned immunosuppressive placebo responses increased efficacy of immunosuppressive medication. These data demonstrate that behavioral conditioning of drug responses may be a promising tool that could be used as a placebo-based dose-reduction strategy in an ongoing immunopharmacological regimen, the aim being to limit unwanted drug adverse effects and to improve treatment efficacy.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Zusammenfassung Hintergrund Systemische Entzündungsprozesse gehen mit unspezifischen körperlichen und psychischen Krankheitssymptomen einher, darunter Schmerz und affektbezogene Symptome. Diese immunvermittelten Symptome („Sickness Behavior“) beruhen auf der zentralnervösen Wirkung von Immunbotenstoffen wie proinflammatorischen Zytokinen und vermitteln bei akuten Entzündungsreaktionen, etwa nach einer Impfung oder Verletzung, ein adaptives Schonverhalten. Bei chronischen Entzündungsprozessen können die Symptome des Sickness Behavior jedoch zu Einschränkungen der Lebensqualität führen und zur Komorbidität bei chronischen Schmerzerkrankungen beitragen. Trotz der hohen klinischen Relevanz des Sickness Behavior wurden bisher psychologische Ansätze zur Modulation der immunvermittelten Sickness-Symptome kaum untersucht. Einen Ansatz könnte die Nutzung von Erwartungseffekten bieten, da positive und negative Erwartungen (Placebo- bzw. Nocebo-Effekte) nachweislich einen Einfluss auf Schmerz und affektbezogene Symptome haben. Ziel der Arbeit In dieser Übersichtsarbeit werden die immunologischen und psychobiologischen Faktoren, die zu Schmerz im Kontext des Sickness Behavior beitragen, zusammengefasst. Aufbauend wird diskutiert, wie durch positive und negative Erwartungen Sickness-Symptome beeinflusst werden können und welche biologischen und psychologischen Mechanismen dabei involviert sind. Ziel ist es, potenzielle Ansatzpunkte zur Optimierung von Erwartungen im Kontext immunvermittelter Sickness-Symptome zu identifizieren. Perspektivisch lassen sich darauf aufbauend Interventionen entwickeln, um diese Symptome zu reduzieren sowie die Wirkungen und Nebenwirkungen von immunassoziierten Therapien durch gezielte Erwartungsinduktionen im Rahmen der Kommunikation mit Patient:innen positiv zu beeinflussen.

Background A long duration of untreated illness (DUI) is an unfavorable prognostic factor in anorexia nervosa (AN) and is associated with chronic illness progression. Although previous preventive measures aimed at reducing DUI and thus improving short- and long-term treatment outcomes have been partially successful, a better understanding of the factors involved in the sensitive phase prior to treatment initiation is needed. To date, there is no validated instrument available to assess these factors specifically for patients with AN. The FABIANA-project (Facilitators and barriers in anorexia nervosa treatment initiation) aims at identifying predictors of the DUI in order to target preventive measures better in the future. As part of this project, the FABIANA-checklist was developed, based on a multi-informant perspective and a multimodal bottom-up approach. The present study focusses on the process of item generation, item selection and psychometric validation of the checklist. Methods Based upon a previous qualitative study, an initial set of 73 items was generated for the most frequently mentioned facilitators and barriers of treatment initiation in AN. After a process of consensual rating and cognitive pre-testing, the resulting 25-item version of the FABIANA-checklist was provided to a sample of female patients (N = 75), aged ≥ 14 years with AN that underwent their first psychotherapeutic treatment in the last 12 months. After item analysis, dimensionality of the final version of the FABIANA-checklist was tested by Principal Component Analysis (PCA). We evaluated construct validity assuming correlations with related constructs, such as perceived social support (F-SozU), support in the health care system (PACIC-5A), illness perception and coping (BIPQ). Results We included 54 adult and 21 adolescent patients with AN, aged on average 21.4 years. Average BMI was 15.5 kg/m2, age of onset was 19.2 years and average DUI was 2.25 years. After item analysis, 7 items were excluded. The PCA of the 18-item-FABIANA-checklist yielded six components explaining 62.64% of the total variance. Overall internal consistency was acceptable (Cronbach’s α = .76) and construct validity was satisfactory for 14 out of 18 items. Two consistent components emerged: “primary care perceived as supportive and competent” (23.33%) and “emotional and practical support from relatives” (9.98%). With regard to the other components, the heterogeneity of the items led to unsatisfactory internal consistency, single item loading and in part ambiguous interpretability. Conclusions The FABIANA-checklist is a valid instrument to assess factors involved in the process of treatment initiation of patients with AN. Psychometrics and dimensionality testing suggests that experienced emotional and practical support from the primary health care system and close relatives are main components. The results indicate that a differentiated assessment at item level is appropriate. In order to quantify the relative importance of the factors and to derive recommendations on early-intervention approaches, the predictive effect of the FABIANA-items on the DUI will be determined in a subsequent study which will further include the perspective of relatives and primary caregivers. Trial registration Clinical Trials.gov Identifier: NCT03713541: https://clinicaltrials.gov/ct2/show/NCT03713541.

No abstract